The ASCO Post

Pembrolizumab/Olaparib Strategy in BRCA-Nonmutated Advanced Ovarian Cancer

A pembrolizumab/olaparib strategy significantly improved progression-free survival in patients with newly diagnosed BRCA-nonmutated advanced epithelial ovarian cancer, although overall survival was not improved, according to results from the phase III ENGOT-OV43/GOG-3036/KEYLYNK-001 trial, which evaluated pembrolizumab plus chemotherapy followed by pembrolizumab/olaparib maintenance.

ASTRO Issues Its First Clinical Guideline on Radiation Therapy for Bladder Cancer

The recommendations support trimodal therapy as a curative alternative to radical cystectomy for select patients and define radiotherapy’s role after surgery and in advanced disease.

Are Narrower Negative Margins Linked to Higher Risk of DCIS Recurrence?

Researchers explored whether the currently recommended 2-mm margin width is necessary to reduce recurrence risk after breast-conserving surgery for ductal carcinoma in situ (DCIS).

FDA Launches Effort to Expand Scientific Expertise, Consumer Voice to Advisory Committees

The U.S. Food and Drug Administration (FDA) will consider nominations for current and anticipated near-term vacancies and will accept nominations on a continuing basis. Nominations for scientific, technical, professional, and other voting-member positions should be submitted no later than November 30, 2026.

Annual Report to the Nation: Progress Against Lung Cancer Drives Down Cancer Mortality

Cancer death rates fell for both men and women from 2019 to 2023, continuing a downward trend that has lasted more than 20 years, according to the 2026 Annual Report to the Nation on the Status of Cancer. The continued decline in cancer deaths is driven largely by accelerated progress against lung cancer.

Lung Cancer: AI Model May Predict Pneumonitis Risk From Immunotherapy

Deep learning may be able to predict pneumonitis risk from immune checkpoint inhibitors in patients with lung cancer based on baseline computed tomography scans, research suggests.